openPR Logo
Press release

Cystinosis Pipeline and Clinical Trials 2023: Latest FDA Approvals, Therapeutic Advancements, Treatment, and Key Players by DelveInsight Featuring Avrobio, Inc., Gilead, Mylan N.V., Novartis AG, Orizon Pharma Plc, Nacuity Pharmaceuticals

12-14-2023 04:48 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Cystinosis Pipeline

Cystinosis Pipeline

(New York, USA) DelveInsight's 'Cystinosis Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline Cystinosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cystinosis pipeline domain.

Request for Cystinosis sample pages @ https://www.delveinsight.com/report-store/cystinosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Cystinosis Pipeline Report
• Over 5+ Cystinosis pipeline therapies are in various stages of development, and their anticipated acceptance in the Cystinosis market would significantly increase market revenue.
• Leading Cystinosis companies developing novel drug candidates to improve the Cystinosis treatment landscape include Avrobio, Inc., Gilead, Mylan N.V., Novartis AG, Orizon Pharma Plc, Nacuity Pharmaceuticals, and others.
• Promising Cystinosis pipeline therapies in various stages of development include AVR RD 04, NP-3, and others.
• AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting.

Request for free sample pages @ https://www.delveinsight.com/sample-request/cystinosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Cystinosis Overview
Cystinosis is a condition characterized by accumulation of the amino acid cystine (a building block of proteins) within cells. Excess cystine damages cells and often forms crystals that can build up and cause problems in many organs and tissues.

Cystinosis Pipeline Analysis: Drug Profile
AVR RD 04: AVROBIO
AVROBIO's investigational gene therapy for cystinosis is being studied in a Phase 1/2 investigational trial sponsored by the University of California, San Diego. The first patient was dosed in October 2019. The single-arm trial is expected to enroll four adults and a potential follow-on cohort of two adults or adolescents at least 14 years of age who are currently being treated with cysteamine, the standard of care for cystinosis.

Discover more about the emerging Cystinosis drugs @ https://www.delveinsight.com/sample-request/cystinosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Cystinosis Pipeline Therapeutics Assessment
• By development stage
• By product type
• By route of administration
• By molecule type
• By MOA type

Scope of the Cystinosis Pipeline Report
• Coverage: Global
• Key Cystinosis Companies: Avrobio, Inc., Gilead, Mylan N.V., Novartis AG, Orizon Pharma Plc, Nacuity Pharmaceuticals, and others
• Key Cystinosis Pipeline Therapies: AVR RD 04, NP-3, and others

Find out more about the Cystinosis treatment options in development @ https://www.delveinsight.com/sample-request/cystinosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Introduction
2. Executive Summary
3. Cystinosis Overview
4. Cystinosis Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Cystinosis Preclinical Stage Products
9. Discovery Stage Products
10. Cystinosis Therapeutic Assessment
11. Inactive Cystinosis Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Cystinosis Unmet Needs
14. Cystinosis Market Drivers and Barriers
15. Appendix
16. About DelveInsight

Trending Reports:
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Chronic Pruritus Market: https://www.delveinsight.com/report-store/chronic-pruritus-market
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/orthotic-devices-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market

Contact Us
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cystinosis Pipeline and Clinical Trials 2023: Latest FDA Approvals, Therapeutic Advancements, Treatment, and Key Players by DelveInsight Featuring Avrobio, Inc., Gilead, Mylan N.V., Novartis AG, Orizon Pharma Plc, Nacuity Pharmaceuticals here

News-ID: 3326886 • Views:

More Releases from DelveInsight Business Research

Triple Negative Breast Cancer Market Forecast 2034 - FDA Approvals, Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight
Triple Negative Breast Cancer Market Forecast 2034 - FDA Approvals, Clinical Tri …
DelveInsight's "Triple Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Triple Negative Breast Cancer, historical and forecasted epidemiology as well as the Triple Negative Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Triple Negative Breast Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and
Relapsed/Refractory Multiple Myeloma Clinical Trial Pipeline Expands as 55+ Companies Driving Innovation in Relapsed/Refractory Multiple Myeloma Therapeutics | DelveInsight
Relapsed/Refractory Multiple Myeloma Clinical Trial Pipeline Expands as 55+ Comp …
DelveInsight's, "Relapsed/Refractory Multiple Myeloma Pipeline Insight, 2025" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Relapsed/Refractory Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. DelveInsight's report, "Relapsing Refractory Multiple Myeloma Pipeline Insight 2025,"
PD-L1 Inhibitors Market Set for Robust Growth Across 7MM, Driven by Novel Immunotherapies, Combination Strategies, and Expanding Indications | DelveInsight
PD-L1 Inhibitors Market Set for Robust Growth Across 7MM, Driven by Novel Immuno …
The global PD-L1 inhibitors market is poised for substantial growth over the next decade, reflecting the transformative impact of immunotherapy on cancer treatment. In 2023, the PD-L1 inhibitors market across the seven major markets (7MM) reached approximately USD 36 billion, with the United States accounting for the largest share. According to DelveInsight's latest report, "PD-L1 Inhibitors Market Insight, Epidemiology and Market Forecast - 2034", the PD-L1 inhibitors market in the seven
BCL-2 Inhibitors Market Poised for Transformative Growth Driven by Next-Generation Oncology Therapies and Expanding Clinical Pipeline | DelveInsight
BCL-2 Inhibitors Market Poised for Transformative Growth Driven by Next-Generati …
(Albany, USA) - The BCL-2 inhibitors market is on the cusp of remarkable expansion over the next decade, propelled by increasing cancer incidence, growing awareness of apoptosis-targeting therapies, and the rapid evolution of clinical research in hematologic malignancies. According to DelveInsight's latest market report, "B-Cell Leukemia/Lymphoma-2 (BCL-2) Inhibitors Market Size, Epidemiology, Competitive Landscape, and Market Forecast - 2034," the global market is expected to experience substantial growth across the United

All 5 Releases


More Releases for Cystinosis

Cystinosis Market 2025-2034 Business Outlook, Critical Insight and Growth
Introduction Cystinosis is a rare, inherited lysosomal storage disorder caused by the accumulation of cystine within cells, leading to progressive damage to multiple organs, including the kidneys, eyes, muscles, pancreas, and thyroid. If left untreated, it results in renal Fanconi syndrome, growth retardation, photophobia, and eventually kidney failure. The disease is typically diagnosed in infancy or early childhood, and without intervention, life expectancy is severely reduced. Over the past two decades, cysteamine-based
Cystinosis FDA Approvals, Clinical Trials and Pipeline Insights 2024 | AVROBIO, …
DelveInsight's 'Cystinosis Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Cystinosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cystinosis pipeline domain. Request for a detailed Cystinosis pipeline sample report @ https://www.delveinsight.com/report-store/cystinosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr Key Takeaways from the Cystinosis Pipeline Report Over 5+ Cystinosis pipeline therapies are in various stages of development, and their anticipated
Nephropathic Cystinosis Treatment Market Surges with Innovative Drug Development …
The Nephropathic Cystinosis Treatment Market sector is undergoing significant transformation, with substantial growth and technological advancements expected by 2031. According to a new in-depth market research report, the sector is poised for expansion, driven by various factors such as market size, share, and emerging trends. This comprehensive report provides key insights into the Nephropathic Cystinosis Treatment market, exploring critical market segmentation and definitions. It highlights the essential components driving growth, offering
Global Cystinosis Treatment Market Share Analysis - Industry Trends and Forecast …
Cystinosis Treatment Market Insights: Trends, Drivers, and Outlook 2024 - 2031 Cystinosis Treatment Market Scope: Unveiling Today's Trends Cystinosis Treatment involves therapies aimed at managing a rare genetic disorder characterized by the accumulation of cystine within cells. The market for Cystinosis Treatment has experienced significant advancements, with an increasing focus on innovative therapies and diagnostics. The rise in awareness about this rare condition, coupled with ongoing research and development activities, has propelled
Cystinosis FDA Approvals, Clinical Trials and Pipeline Insights 2024 | AVROBIO, …
DelveInsight's 'Cystinosis Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Cystinosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cystinosis pipeline domain. Request for a detailed Cystinosis pipeline sample report @ https://www.delveinsight.com/report-store/cystinosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr Key Takeaways from the Cystinosis Pipeline Report Over 5+ Cystinosis pipeline therapies are in various stages of development, and their anticipated
Nephropathic Cystinosis Treatment Market: A Comprehensive Analysis
The Nephropathic Cystinosis Treatment Market has witnessed significant growth in recent years, driven by advancements in research, therapeutic approaches, and a growing emphasis on multidisciplinary patient care. This article provides a comprehensive analysis of the market, encompassing market size, growth trends, key players, competitive landscape, consumer behavior, emerging technologies, regulatory environment, and future outlook. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚 𝐬𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 (𝐔𝐬𝐞 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐌𝐚𝐢𝐥 𝐈𝐝 𝐟𝐨𝐫 𝐐𝐮𝐢𝐜𝐤 𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐞) -